Direct Acting Antiviral HCV Therapy is Safe and Effective in Patients with Decompensated Cirrhosis: Real World Experience from the HCV-TARGET Cohort
Verna EC, Morelli G, Terrault N, Lok AS, Lim J, Di Bisceglie AM, Zeuzem S, Landis C, Lutchman G, Hassan M, Manns M, Vainorius M, Akushevich L, Nelson D, Fried M, Reddy KR
2017
EASL
Incidence of and predictors for direct acting antiviral treatment failure among 4099 hepatitis C genotype 1 infected adults: Real world outcomes from HCV TARGET
Sulkowski, MS; Reddy, R; Nelson, DR, Lim, JK; Galati, JS; Kuo, A; Terrault, N; Lok, AS; Pearlman, BL; Vainorius, M; Akushevich, L; Fried, MW; Di Bisceglie, AM
2017
EASL
Safety and Efficacy of Sofosbuvir and Velpatasvir with or without Ribavirin for the Treatment of HCV Genotype 1-6: Results of the HCV-TARGET Study
Khalili, M; Welzel, TM; Terrault, N; Lim, J; Sridhar, A; Lutchman, G; Nelson, D; Borg, B; Lok AS; Ramani, A; Reau, N; Vainorius, M; Fried, MW; Landis, C
2017
EASL
Safety and Efficacy of Elbasvir and Grazoprevir with or without Ribavirin for the Treatment of HCV Genotype 1: Results of the HCV-TARGET Study
Pearlman, BL; Lutchman, G; Shiffman, ML; Patel, J; Frazier, LM; Galati, JS; Gallant, JE; Ramani, A; Vainorius, M; Nelson, DR; Fried, MW; Dong, M; Khalili, M; Ben-Ari, Z
2016
AASLD
Safety and Tolerability of Direct Acting Antiviral Agents (DAAs) Used in Usual Clinical Practice: HCV-TARGET International Consortium
Michael W. Fried, K. Rajender Reddy, Mitchell L. Shiffman, Stefan Zeuzem, Norah Terrault, Alexander Kuo, Paul J. Pockros, Mark S. Sulkowski, Michael P. Manns, Jacqueline G. O'Leary, Lucy Akushevich, Monika Vainorius, David R. Nelson, Joseph K. Lim
2016
APASL
SAFETY AND EFFICACY OF ORAL REGIMENS FOR THE TREATMENT OF HEPATITIS C GENOTYPE 1b INFECTION: HCV-TARGET INTERIM ANALYSIS OF A PROSPECTIVE, OBSERVATIONAL STUDY
Manns M, Nelson DR, Zeuzem S , Di Bisceglie AM, Ben-Ari, Z, Lok AS, Pockros P, Lim JK, Kuo A, Reddy R, Frazier L, Stewart P, Vainorius M, Sulkowski MS, Fried MW
2016
EASL-AASLD Spec Conf Sept2016
SAFETY AND EFFECTIVENESS OF 12 AND 24-WEEK REGIMENS OF LEDIPASVIR/SOFOSBUVIR (LDV/SOF) IN TREATMENT EXPERIENCED GENOTYPE 1 CIRRHOSIS: INTERIM ANALYSIS HCV-TARGET, A PROSPECTIVE, OBSERVATIONAL STUDY
ML Shiffman , JK Lim, AS Lok , S Zeuzem, N Terrault, JS Park, CS Landis, M Hassan, JE Gallant, AA. Kuo, PJ Pockros, M Vainorius, L Akushevich, MW Fried, DR Nelson, Z Ben-Ari
2016
EASL-AASLD Spec Conf Sept2016
SAFETY AND EFFECTIVENESS OF 12 AND 24-WEEK REGIMENS OF PARITAPREVIR/R, OMBITASVIR, DASABUVIR (PrOD) FOR THE TREATMENT OF HEPATITIS C GENOTYPE 1A INFECTION: INTERIM ANALYSIS HCV-TARGET, A PROSPECTIVE, OBSERVATIONAL STUDY
ML Shiffman , JK Lim, AS Lok , S Zeuzem, N Terrault, JS Park, CS Landis, M Hassan, JE Gallant, AA. Kuo, PJ Pockros, M Vainorius, L Akushevich, MW Fried, DR Nelson, Z Ben-Ari
2016
EASL
Prevalence and Impact of
Baseline Resistance-Associated Variants (RAVs) on the Efficacy of Ledipasvir/Sofosbuvir or Simeprevir/Sofosbuvir Against GT1 HCV Infection: HCV-TARGET Interim Analysis
Gary P. Wang, Jackie Reeves, Norah Terrault, Joseph Lim, Giuseppe Morelli, Alexander Kuo, Josh Levitsky, Kenneth Sherman, Lynn M. Frazier, Ananthakrishnan Ramani, Joy Peter, Lucy Akuskevich, Michael W. Fried, David R. Nelson
2016
EASL
Safety and Efficacy of New DAA Regimens in Kidney and Liver Transplant Recipients with Hepatitis C: Interval Results from the HCV-TARGET Study
Reddy KR, Sulkowski MS, Hassan M, Levitsky J, O’Leary JG, Brown RS, Kuo A, Stravitz T, Lim JK, Verna E, Saxena V, Nelson DR, Hayashi P, Vainorius M, Fried MW, Terrault N
2015
AASLD
SAFETY AND EFFICACY OF SOFOSBUVIR AND RIBAVIRIN FOR THE TREATMENT OF HCV GENOTYPE 2 AND 3: RESULTS OF THE HCV-TARGET STUDY
Welzel TM, Nelson DR, Morelli G, Di Bisceglie AM, Reddy KR, Kuo A, Lim JK, Darling JM, Pockros PJ, Galati JS, Frazier LM, Alqahtani S, Sulkowski MS, Fried MW, Zeuzem S
2015
AASLD
Treatment Outcomes With 8, 12 and 24 Week Regimens of Ledipasvir/Sofosbuvir for the Treatment of Hepatitis C Infection: Analysis of a Multicenter Prospective, Observational Study
N Terrault, S Zeuzem, AM Di Bisceglie, JK Lim, PJ Pockros, LM Frazier, A Kuo, AS Lok, ML Shiffman, Z Ben Ari, T Stewart, MS Sulkowski, MW Fried, and DR Nelson
2015
ATC
Safety and Efficacy of All Oral DAA Therapy for Genotype 1 HCV Post-Liver Transplant: Interval Results form the HCV TARGET Multicenter Prospective Observational Study
J.G. O'Leary, R.S. Brown, K.R. Reddy, A. Kuo, G. Morelli, R.T. Stravitz, G.T. Everson, C.M. Durand, H.E.
Vargas, P. Kwo, C.T. FreneQe, J.A. Peter, M. Vainorius, L. Akushevich, D.R. Nelson, M.W. Fried, N. Terrault
2015
EASL
All Oral HCV Therapy is Safe and Effective in Patients with Decompensated Cirrhosis: Report from HCV-TARGET
K. Rajender Reddy, Joseph K. Lim, Alexander Kuo, Adrian M. Di Bisceglie, Hugo E. Vargas, Joseph S. Gala8,
Giuseppe Morelli, Gregory T. Everson, Paul Kwo, Robert S.
Brown, Mark S. Sulkowski, Lucy Akushevich, Thomas G. Stewart, Monika Vainorius, Joy A. Peter, David Nelson, Michael W. Fried, Michael P. Manns
2015
EASL
Safety and Efficacy of Sofosbuvir-Containing Regimens in Hepatitis C Infected Patients with Reduced Renal Function: Real-World Experience from HCV-TARGET
V Saxena, FM Koraishy, M Sise, JK Lim, RT Chung, A Liapakis, DR Nelson, M Schmidt, MW Fried, N Terrault
2015
EASL
SAFETY AND EFFECTIVENESS OF SOFOSBUVIR-BASED REGIMENS FOR THE TREATMENT OF HEPATITIS C GENOTYPE 3 & 4 INFECTIONS: INTERIM ANALYSIS OF A PROSPECTIVE, OBSERVATIONAL STUDY
Alqahtani S, Zeuzem S, Manns MP, Kuo A, Di Bisceglie AM, Reddy R, Mailliard M, O’Leary J, Pockros P, Kwo PY, Lim JK, Vargas HE, Fried MW, Nelson DR, Sulkowski MS
2015
HEPDART
HCV Therapies in Clinical Practice: HCV-TARGET Studies
Michael W. Fried, M.D., FAASLD
2015
HCV-TARGET International Registry Do Phase III Trials Translate into Real World
David R Nelson, MD
2014
AASLD
Safety and Efficacy of Sofosbuvir in Combination with Simeprevir +/- Ribavirin in Patients with Genotype 1: Interim Results of a Prospective, Observational Study
Sulkowski MS, Vargas HE, Di Bisceglie AM, Kuo, A, Reddy KR, Lim JK, Morelli G, Feld JJ, Brown RS, Frazier LM, Fried MW, Nelson DR, Jacobson IM
2014
Safety and Efficacy of New DAA‐based
Therapy for Hepatitis C Post‐Transplant: Interval Results from the HCV‐TARGET Longitudinal, Observational Study
Brown, Jr. RS, Reddy KR, O'Leary JG, Kuo A, Morelli G, Stravitz RT, Durand C, Di Bisceglie AM, Vargas HE, Kwo P, FreneGe CT, Vainorius M, Akushevich L, Fried MW, Terrault N
2014
Safety and Efficacy of Sofosbuvir‐Containing Regimens for Hepatitis C: Real‐World Experience in a Diverse, Longitudinal Observational Cohort
Jensen DM, O’Leary J, Pockros P, Sherman K, Kwo P, Mailliard M, Kowdley K, Muir A, Dickson R, Ramani A, Manns M, Lok A, Akushevich L, Nelson D and Fried M
2013
AASLD
Safety and Efficacy of Telaprevir (TPV) or Boceprevir (BOC) in Patients with Cirrhosis:
Interim Results of a Longitudinal, Observational Study
Afdahl NH, Reau N, Everson GT, Morelli G, Lok AS, Sherman KE, Dickson RC, Regenstein F, Mena EA, Stewart TG, Fried MW, Pockros P
2013
AASLD
The Frequency and Management of Adverse Events in Chronic Hepatitis C (HCV) Treated with Boceprevir or Telaprevir: Real World Experience from HCV-TARGET Longitudinal Observational Study
Gordon SC, Muir AJ, Lim JK, Pearlman BL, Argo CK, Neff GW, Ramani A, Maliakkal B, Rodriguez-Torres M, Stewart TG, Fried MW, Reddy KR
2013
EASL
HCV-TARGET: A LONGITUDINAL, OBSERVATIONAL STUDY OF NORTH AMERICAN PATIENTS WITH CHRONIC HEPATITIS C (HCV) TREATED WITH BOCEPREVIR OR TELAPREVIR
M.W. Fried, K.R. Reddy, A.M. Di Bisceglie, D.M. Jensen, I.M. Jacobson, M.S. Sulkowski, N.A. Terrault, N.H. Afdhal, S.C. Gordon, P.J. Pockros, P.Y. Kwo, G.T. Everson, K.E. Sherman, A.J. Muir, B.L. Pearlman, T.G. Stewart, M. Vainorius, J.A. Peter, D.R. Nelson
2013
HEPDART
HCV Treatment Selection and Duration Decision-Making: Real-World Issues with HCV RNA and HCV Genotype Assays Used in Clinical Practice
MW Fried, M Vainorius, KR Reddy, AM Di Bisceglie, DM Jensen, IM Jacobson, M Sulkowski, N Terrault, K Bergquist, TG Stewart, JA Peter, and DR Nelson
2013
Impact of Age on Safety and Treatment Response in Patients with Hepatitis C (HCV) Treated with Boceprevir or Telaprevir
A. Aronsohn, T Stainbrook, S Mohanty, A Mubarak, J Spivey, P Prashant, T Stewart, MW Fried, I Jacobson
2013
Pre-treatment Education and Treatment Completion in Patients with Hepatitis C (HCV)
Treated with Boceprevir (BOC) or Telaprevir (TVR)
Mercier DA, Appolo BA, Cardona D, Stewart TG, Vainorius M, Scherschel A, Horne P,
Hubbard SB, Keller AL, Richards L, Peter J
2013
Virological Outcomes and Adherence to Treatment Algorithms in a Longitudinal Study of Patients with Chronic Hepatitis C Treated with Boceprevir or Telaprevir
in the U.S. (HCV-TARGET)
AM Di Bisceglie, A Kuo, VK Rustgi, MS Sulkowski, TG Stewart, JM Fenkel, H ElGenaidi, M Mah’moud, GM Abraham, MW Fried, RK Sterling
Recent Comments